covid
Buscar en
Endocrinología y Nutrición
Toda la web
Inicio Endocrinología y Nutrición Paciente con alteración de la conducta
Journal Information
Vol. 54. Issue 4.
Pages 232-235 (April 2007)
Share
Share
Download PDF
More article options
Vol. 54. Issue 4.
Pages 232-235 (April 2007)
Notas clínicas
Full text access
Paciente con alteración de la conducta
Patient with behavioral alterations
Visits
5132
Edurne Lecumberri
Corresponding author
edurnelecumberri@hotmail.com

Correçpondencia: Dra. E. Lecumberri. Secretaría de Endocrinología y Nutrición. Hospital Clínico San Carlos. Prof. Martín Lagos, s/n. 28040 Madrid. España.
, José Ángel Díaz, Natalia Pérez Ferre
Servicio de Endocrinología y Nutrición. Hospital Clínico San Carlos. Madrid. España
This item has received
Article information

El insulinoma constituye el 60% de los tumores que asientan en el páncreas, de los cuales el 90% son benignos y únicos; el 10% son múltiples, la mayoría asociados a MEN 1 y el 5-10% son malignos. La posibilidad de recidiva obliga a un diagnóstico y seguimiento a largo plazo.

Presentamos el caso de un varón de 74 años en el que se inicia un cuadro de alteración de la conducta relacionado con episodios de hipoglucemia repetidos. Tras los resultados del test de ayuno, las pruebas de imagen y la punción-aspiración con aguja fina de la lesión hepática, se diagnostica de insulinoma maligno. Se discute acerca de las distintas opciones diagnósticas y terapéuticas del insulinoma maligno.

Palabras clave:
Insulinoma
Maligno
Metástasis

Sixty percent of pancreatic tumors are insulinomas (90% benign and isolated; 10% multiple, usually associated with multiple endocrine neoplasia type 1, and 5- 10% malignant). Because of the possibility of recurrence, accurate diagnosis and longterm follow-up are essential. We present the case of a 74-year-old man who presented with behavioral alterations related to recurrent hypoglycemic episodes. Fasting test, several imaging techniques, and fine-needle aspiration biopsy of a hepatic lesion were performed and a malignant insulinoma was diagnosed.

We discuss the distinct diagnostic and treatment options in this kind of neoplasm.

Key words:
Insulinoma
Malignant
Metastasis
Full text is only aviable in PDF
Bibliografía
[1.]
A.W.K. Tso, K.S.L. Lam.
Insulinoma.
Curr Opin Endocrinol Diab, 7 (2000), pp. 83-88
[2.]
F.J. Service, A.J. Dale, L.R. Elveback, N.S. Jiang.
Insulinoma: clinical and diagnostic features of 60 consecutive cases.
Mayo Clinic Proc, 51 (1976), pp. 417-429
[3.]
A.M. Dizon, S. Kowalyk, B.J. Hoogwerf.
Neuroglucopenic and other symptoms in patients with insulinomas.
Am J Med, 106 (1999), pp. 307-310
[4.]
M.G. Harrington, A.P. McGeorge, J.P. Ballantyne, G. Beastall.
A prospective survey for insulinomas in a neurology department.
Lancet, 8333 (1983), pp. 1094-1095
[5.]
T. Rosch, C.J. Lightdale, J.F. Botet, G.A. Boyce, M.V. Sivak Jr, K. Yasuda, et al.
Localization of pancreatic endocrine tumors by endoscopic ultrasonography.
N Engl J Med, 326 (1992), pp. 1721-1726
[6.]
I.M. Modlin, L.H. Tang.
Approaches to the diagnosis of gut neuroendocrine tumors: the last word (today).
Gastroenterology, 112 (1997), pp. 583-590
[7.]
S. Lamberts, W. Bakker, J. Reubi, E. Krenning.
Somatostatin receptor imaging in the localization of endocrine tumors.
N Engl J Med, 323 (1990), pp. 1246-1249
[8.]
M. Stivanello, A. Berruti, M. Torta, A. Termine, M. Tampellini, G. Gorzegno, et al.
Circulating chromogranin A in the assesment of patients with neurondocrine tumors. A single institution experience.
Ann Oncol, 12 (2001), pp. S73-S77
[9.]
E. Janson, L. Holmberg, M. Stridsberg, B. Eriksson, E. Theodorsson, E. Wilander, et al.
Carcinoid tumors: Analysis of prognostic factors and survival in 301 patients from a referral center.
Ann Oncol, 8 (1997), pp. 685-690
[10.]
L. Kvols, C. Moertel, M. O’Connell, A.J. Schutt, J. Rubin, R.G. Hahn.
Treatment of the malignant carcinoid syndrome: Evaluation of a long-acting somatostatin analog.
N Engl J Med, 315 (1986), pp. 663-666
[11.]
H. Shojamanesh, F. Gibril, A. Louie, J.V. Ojeaburru, S. ashir, A. Abou-Saif, et al.
Prospective study of the antitumor efficacy of long-term octreotide treatment in patients with progerssive metastatic gastrinoma.
Cancer, 94 (2002), pp. 331-343
[12.]
F. Que, D. Nagorney, K. Batts, L.J. Linz, L.K. Kvols.
Hepatic resection for metastatic neuroendocrine carcinomas.
Am J Surg, 169 (1995), pp. 36-42
[13.]
J.G. Drougas, L.B. Anthony, T.K. Blair, R.R. Lopez, J.K. Wright Jr, W.C. Chapman, et al.
Hepatic artery chemoembolization for management of patients with advanced metastatic carcinoid tumors.
Am J Surg, 175 (1998), pp. 408-412
[14.]
S.A. Gulec, T.S. Mountcastle, D. Frey, J.D. Cundiff, E. Mathews, L. Anthony, et al.
Cytoreductive surgery in patients with advanced-stage carcinoid tumors.
Am Surg, 68 (2002), pp. 667-671
Copyright © 2007. Sociedad Española de Endocrinología y Nutrición
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos